Author: Optogenerapy News

Optogenerapy > Articles posted by Optogenerapy News (Page 3)
ptogenerapy_interview_Encarna_Escudero

From the invention of the first man-made plastic in 1862, the plastic industry has grown exponentially in materials and techniques making impossible, nowadays, to imagine a modern life without plastics. With a vast expertise in plastic injection moulding processes, Optogenerapy’s partner Eurecat brings to the project its expertise on the manufacture of micro and mini plastic pieces by ultrasounds, a ground-breaking concept for the production...

Read More
Optogenerapy Cluster MAV Catalonia Bio&Health Tech Workshop

Barcelona, 6th April, 2018 – Project partner Eurecat delivered a talk on Optogenerapy concept and expected impacts during the 1st Exploration Workshop organized by Connecting CataloniaBio&Health Tech and Advanced Materials Cluster on April 6th at ACCIO facilities.   During the presentation, titled as “Biomaterials for the development of a bioelectronic device for the treatment of Multiple Sclerosis”, speaker Esther Hurtos focused on explaining the development of a...

Read More
optogenerapy LOPEC Poster

Munich, 14th March, 2018 – Optogenerapy partner Mohammad Mashayekhi from Eurecat has presented the poster "Compact Low-resistance Screen-printed Flexible Antennas for NFC Applications” at LOPEC 2018, the world’s leading event and the most important congress for the printed electronics industry covering all areas of the value chain.   The poster addresses the technology used by Eurecat for the development of the electronics of the Optogenerapy’s solution from...

Read More
optogenerapy_meeting_1year_INSERM

Paris, 23rd February, 2017 – Optogenerapy’s consortium has met in Paris at INSERM facilities for the project’s third meeting, marking one year after the start of the project. At the meeting, partners reviewed the advances in each of the work packages and planned and prepared upcoming milestones and tasks.   During the first year of the project, partners addressed the design and development of the implant, including...

Read More

The success of modern medicine results from a synergy between the development of drug delivery devices and the ever-growing drug industry. The Optogenerapy solution aims at disrupting the current drug delivery techniques proposing a cell-based implant able to produce a drug of interest directly inside the patient.   Project partner ETH-Zurich recently published a paper on this innovative solution. In this interview, Marc Folcher, senior scientist and...

Read More

Berlin, 20th October, 2017 – The EU-funded Optogenerapy project was presented at the XXV Anniversary Congress of the European Society of Gene and Cell Therapy (ESGCT), which took place the 17th - 20th of October 2017 in Berlin, Germany. During the second day of the Congress, partners exhibited the poster “Bio-electronic cell-based implant to deliver beta interferon”, explaining the methodology and objectives behind the project.   For...

Read More

Barcelona, 11th September, 2017 – The Optogenerapy consortium will be gathered together for its second meeting after the project’s kick-off in February. The meeting, hosted by the project’s partner ETHZ, the Swiss Federal Institute of Technology Zurich, will take place in Basel on September 14th and 15th.   The first six months of the project have been busy in defining specifications and designing the first pieces of...

Read More

The paper “Optogenerapy: When bio-electronic implant enters the modern syringe era”, breaking down the latest advances of the multidisciplinary technologies behind Optogenerapy’s project, has been published at Porto Biomedical Journal by Fanny Michel and Marc Folcher, two scientifics and lecturers from the Department of Biosystems Science and Engineering of ETH Zurich. ETH Zurich is one of the top leading international universities for technology and natural...

Read More

Barcelona, 1st June, 2017 – Researchers from eleven institutions and companies in seven different European countries have started work within the Optogenerapy consortium to develop optogenetic cellular therapy implants by means of printed electronics with biocompatible materials that will enable the administration of therapeutic protein doses for patients with multiple sclerosis, an illness that affects 2.3 million people all over the world and 700,000 in...

Read More

Barcelona 20th February, 2017 - Researchers from eleven institutions and companies in seven different European countries met at Eurecat’s facilities in Cerdanyola del Vallès (Barcelona) to launch the Optogenerapy project, which aims to develop optogenetic cellular therapy implants as a new treatment for Multiple Sclerosis.   The devices, based on technology developed at the Swiss Federal Institute of Technology in Basel, member of the consortium, will enable the...

Read More
Optogenerapy